{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:15:16Z","timestamp":1790712916910,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Peptidylglycine alpha-amidating monooxygenase (PAM) is the only enzyme known to catalyze C-terminal amidation, a final post-translational modification step essential for the biological activity of over 70 bioactive peptides, including adrenomedullin (ADM), calcitonin gene-related peptide (CGRP), amylin, neuropeptide Y (NPY), and others. Bioactive (amidated) peptide hormones play crucial roles in various physiological processes and have been extensively explored as therapeutic compounds in clinical and preclinical research. However, their therapeutic viability is limited due to their short half-life and, in most cases, the need for prolonged infusion to maintain effective concentrations. PAM itself has also been considered as a therapeutic compound aiming to increase the level of amidated peptide hormones; however, similarly to peptide hormones, PAM\u2019s rapid degradation limits its utility. Here, we present a strategy to enhance PAM stability and bioavailability through PEGylation, significantly extending the enzyme\u2019s half-life in circulation assessed in healthy rats. Furthermore, single subcutaneous (s.c.), intramuscular (i.m.), or intraperitoneal (i.p.) administration of PEGylated PAM resulted in a sustained increase in circulating amidating activity, with peak activity observed at 12\u201324 h post-bolus administration. Notably, amidating activity remained significantly elevated above baseline levels for up to seven days post-administration, with no observable adverse effects. These findings highlight PEGylated PAM\u2019s potential as a viable therapeutic compound.<\/jats:p>","DOI":"10.3390\/biom15020224","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:13:43Z","timestamp":1738646023000},"page":"224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing Stability and Bioavailability of Peptidylglycine Alpha-Amidating Monooxygenase in Circulation for Clinical Use"],"prefix":"10.3390","volume":"15","author":[{"given":"Yulia","family":"Ilina","sequence":"first","affiliation":[{"name":"PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Press","sequence":"additional","affiliation":[{"name":"PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo Ikenna","family":"Uba","sequence":"additional","affiliation":[{"name":"4TEEN4 Pharmaceuticals GmbH, 16761 Hennigsdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bergmann","sequence":"additional","affiliation":[{"name":"PAM Theragnostics GmbH, 16761 Hennigsdorf, Germany"},{"name":"4TEEN4 Pharmaceuticals GmbH, 16761 Hennigsdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"T63","DOI":"10.1530\/JME-15-0266","article-title":"60 YEARS OF POMC: From POMC and \u03b1-MSH to PAM, molecular oxygen, copper, and vitamin C","volume":"56","author":"Kumar","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/B978-0-12-385095-9.00244-X","article-title":"Peptidylglycine Amidating Monoxygenase (PAM)","volume":"3","author":"Vishwanatha","year":"2013","journal-title":"Handbook of Biologically Active Peptides"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.ph.50.030188.002001","article-title":"Peptide \u03b1-Amidation","volume":"50","author":"Eipper","year":"1988","journal-title":"Annu. Rev. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.ne.15.030192.000421","article-title":"The biosynthesis of neuropeptides: Peptide alpha-amidation","volume":"15","author":"Eipper","year":"1992","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14728222.9.5.923","article-title":"Vasoactive intestinal peptide family as a therapeutic target for Parkinson\u2019s disease","volume":"9","author":"Chorny","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/187152710793361595","article-title":"Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders","volume":"9","author":"White","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1076\/apab.109.3.246.11587","article-title":"Diabetes mellitus is associated with a decrease in vasoactive intestinal polypeptide content of gastrointestinal tract of rat","volume":"109","author":"Adeghate","year":"2001","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nbd.2016.07.022","article-title":"Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases","volume":"95","author":"Cavadas","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, C., Wu, X., Liu, S., Zhao, Y., Zhu, J., and Liu, K. (2019). Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00869"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1212\/WNL.0000000000000417","article-title":"Pituitary adenylate cyclase\u2013activating polypeptide is reduced in Alzheimer disease","volume":"82","author":"Han","year":"2014","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2169\/internalmedicine.1791-18","article-title":"Adrenomedullin: A novel therapy for intractable Crohn\u2019s disease with a loss of response to infliximab","volume":"58","author":"Ashizuka","year":"2019","journal-title":"Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41440-021-00806-y","article-title":"Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases","volume":"45","author":"Kita","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/cvd.2012.012003","article-title":"Adrenomedullin and cardiovascular diseases","volume":"1","author":"Wong","year":"2012","journal-title":"JRSM Cardiovasc. Dis."},{"key":"ref_14","first-page":"100007","article-title":"Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment","volume":"2","author":"Ihara","year":"2021","journal-title":"Cereb. Circ. Cogn. Behav."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102901","DOI":"10.1016\/j.eclinm.2024.102901","article-title":"Efficacy and safety of adrenomedullin for acute ischemic stroke (AMFIS): A phase 2, randomized, double-blinded, placebo-controlled, clinical trial","volume":"77","author":"Yoshimoto","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/glia.20681","article-title":"Vasoactive intestinal peptide protects against \u03b2-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels","volume":"56","author":"Delgado","year":"2008","journal-title":"Glia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1465-9921-12-45","article-title":"Prospect of vasoactive intestinal peptide therapy for COPD\/PAH and asthma: A review","volume":"12","author":"Wu","year":"2011","journal-title":"Respir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1381612013398374","article-title":"Immunology of VIP: A Review and Therapeutical Perspectives","volume":"7","author":"Gomariz","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-018-0845-3","article-title":"Protective effects of PACAP in ischemia","volume":"19","author":"Reglodi","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"DToth, D., Reglodi, D., Schwieters, L., and Tamas, A. (2023). Role of endocrine PACAP in age-related diseases. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1118927"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/978-3-319-35135-3_48","article-title":"PACAP as a Potential Biomarker: Alterations of PACAP Levels in Human Physiological and Pathological Conditions","volume":"11","author":"Reglodi","year":"2016","journal-title":"Pituitary Adenylate Cyclase Activating Polypeptide\u2014PACAP"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1515\/cmble-2015-0008","article-title":"Therapeutic potential of PACAP for neurodegenerative diseases","volume":"20","author":"Yang","year":"2015","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"G\u00e1briel, R., P\u00f6sty\u00e9ni, E., and D\u00e9nes, V. (2019). Neuroprotective Potential of Pituitary Adenylate Cyclase Activating Polypeptide in Retinal Degenerations of Metabolic Origin. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01031"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ciranna, L., and Costa, L. (2019). Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Hippocampal Synaptic Transmission and Plasticity: New Therapeutic Suggestions for Fragile X Syndrome. Front. Cell. Neurosci., 13.","DOI":"10.3389\/fncel.2019.00524"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1096\/fj.10-180133","article-title":"Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice","volume":"25","author":"Rat","year":"2011","journal-title":"FASEB J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Han, P., Tang, Z., Yin, J.-X., Beach, T., Reiman, E., and Shi, J. (2014). PACAP Deficit in Alzheimer\u2019s Disease and Protection Against Beta-Amyloid Toxicity (I11-1.010). Neurology, 82.","DOI":"10.1212\/WNL.82.10_supplement.I11-1.010"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lutz, T.A., and Meyer, U. (2015). Amylin at the interface between metabolic and neurodegenerative disorders. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00216"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuropharm.2017.03.030","article-title":"Amylin receptor ligands reduce the pathological cascade of Alzheimer\u2019s disease","volume":"119","author":"Zhu","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ddr.21383","article-title":"Anti-Inflammatory Effects of PEGylated Human Adrenomedullin in a Mouse DSS-Induced Colitis Model","volume":"78","author":"Nagata","year":"2017","journal-title":"Drug Dev. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/09031936.04.00016103","article-title":"Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure","volume":"24","author":"Kandler","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Geven, C., Kox, M., and Pickkers, P. (2018). Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00292"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1111\/bph.15815","article-title":"Peptidylglycine \u03b1-amidating monooxygenase as a therapeutic target or biomarker for human diseases","volume":"179","author":"Merkler","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.1993.tb01750.x","article-title":"Peptide \u03b1-amidation activity in human plasma: Relationship to gastrin processing","volume":"39","author":"Kapuscinski","year":"1993","journal-title":"Clin. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10142-022-00840-0","article-title":"PAM variants were associated with type 2 diabetes mellitus risk in the Chinese population","volume":"22","author":"Sheng","year":"2022","journal-title":"Funct. Integr. Genom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41588-018-0173-1","article-title":"Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic \u03b2-cells","volume":"50","author":"Thomsen","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Giontella, A., \u00c5kerlund, M., Bronton, K., Fava, C., Lotta, L.A., Baras, A., Overton, J.D., Jones, M., Bergmann, A., and Kaufmann, P. (2024). Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus. J. Clin. Endocrinol. Metab.","DOI":"10.1210\/clinem\/dgae510"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.37.6.1057","article-title":"Alzheimer\u2019s disease: Low levels of peptide alpha-amidation activity in brain and CSF","volume":"37","author":"Wand","year":"1987","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1073\/pnas.2004410117","article-title":"Peptidylglycine \u03b1-amidating monooxygenase is required for atrial secretory granule formation","volume":"117","author":"Luxmi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kaufmann, P., Bergmann, A., and Melander, O. (2021). Novel insights into peptide amidation and amidating activity in the human circulation. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-95305-y"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kaufmann, P., Ilina, Y., Press, M., and Bergmann, A. (2024). Sandwich immunoassay for adrenomedullin precursor and its practical application. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-79542-5"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1006\/bbrc.1998.8310","article-title":"The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma","volume":"244","author":"Kitamura","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1161\/01.ATV.0000184759.91369.f8","article-title":"Adrenomedullin: A Protective Factor for Blood Vessels","volume":"25","author":"Kato","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-Like Peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Manecka, D.L., Boukhzar, L., Falluel-Morel, A., Lihrmann, I., and Anouar, Y. (2016). PACAP signaling in neuroprotection. Pituitary Adenylate Cyclase Activating Polypeptide\u2014PACAP, Springer.","DOI":"10.1007\/978-3-319-35135-3_32"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1211958","article-title":"The role of amylin in the physiology of glycemic control","volume":"106","author":"Scherbaum","year":"1998","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1038\/ijosup.2016.5","article-title":"Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor","volume":"6","author":"Desai","year":"2016","journal-title":"Int. J. Obes. Suppl."},{"key":"ref_47","first-page":"4","article-title":"Vasopressin: Physiology and clinical use in patients with vasodilatory shock: A review","volume":"63","author":"Meinders","year":"2005","journal-title":"Neth. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1601-0825.2010.01717.x","article-title":"Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients","volume":"17","author":"Jang","year":"2011","journal-title":"Oral Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1530\/JOE-16-0223","article-title":"The metabolic syndrome in mice overexpressing neuropeptide Y in noradrenergic neurons","volume":"234","author":"Ailanen","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.12688\/f1000research.16654.1","article-title":"Vasopressin\u2013aquaporin-2 pathway: Recent advances in understanding water balance disorders","volume":"8","author":"Ranieri","year":"2019","journal-title":"F1000Research"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fossmark, R., Qvigstad, G., Martinsen, T.C., Hauso, \u00d8., and Waldum, H.L. (2011). Animal Models to Study the Role of Long-Term Hypergastrinemia in Gastric Carcinogenesis. J. Biomed. Biotechnol., 2011.","DOI":"10.1155\/2011\/975479"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1373\/jalm.2017.023655","article-title":"Sandwich Immunoassay for Bioactive Plasma Adrenomedullin","volume":"2","author":"Weber","year":"2017","journal-title":"J. Appl. Lab. Med."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:31Z","timestamp":1760027191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/2\/224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["biom15020224"],"URL":"https:\/\/doi.org\/10.3390\/biom15020224","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}